Stifel analyst Justin Keywood said on Jan. 8 that WELL Health Technologies (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) could emerge as a strategic beneficiary of TELUS’s decision to pursue a near-term monetization of its TELUS Health division, reiterating a “Buy” rating and C$9.00 target price on WELL. Shares last traded at C$4.08, implying a market capitalization of about C$1.1-billion.
TELUS said it plans to monetize TELUS Health to reduce leverage, a move Keywood believes is more likely to occur through a piecemeal sale or partial spin-out rather than a single transaction, given the diversity of assets within the portfolio. He said residual ownership or partnership structures are also possible, alongside an IPO or spin-out of select businesses. In that context, Keywood views WELL as a “natural acquiror” for certain TELUS Health assets, particularly clinic-based operations, noting that WELL’s disclosed M&A pipeline in Q3/25 expanded roughly fourfold quarter-over-quarter. A transaction, he said, could act as a catalyst for WELL shares, given potential operational and strategic synergies.
Keywood cautioned that competition considerations would likely limit WELL’s ability to pursue TELUS Health’s core EMR software assets, given TELUS Health’s roughly 45% share of the Canadian EMR market compared with WELLSTAR’s estimated 17% share. Even so, he said WELL’s valuation remains depressed as the company continues to streamline operations, creating an opportunity as the business model simplifies and as consolidation opportunities in Canadian healthcare persist.
He outlined TELUS Health as a portfolio anchored by LifeWorks, acquired in 2021, and Workplace Options, which together manage employee and family assistance programs across roughly 200 countries and generate the bulk of TELUS Health’s estimated $2-billion in annual revenue. TELUS Health also operates about 15 Canadian clinic assets integrated with its EMR platform, alongside smaller digital health offerings such as virtual care and pharmacy software. Keywood noted the presence of certain AI-related assets within the division as well.
While stressing he has no visibility into active negotiations, Keywood said WELL could realistically acquire TELUS Health’s clinic assets, while private equity could play a significant role in transactions involving the remaining businesses. He added that TELUS’ existing private equity partner, GCTR, could increase its ownership in Workplace Options following a monetization event, while large insurers such as Manulife, Sun Life or Great-West could show interest in other EFAP assets.
On valuation, Keywood noted TELUS acquired Morneau Shepell at roughly 15x EBITDA in 2021, but applying a more conservative 8x EBITDA exit multiple to the current TELUS Health portfolio implies potential proceeds of about $2.5-billion. He said such proceeds would be sufficient to support TELUS’ goal of reducing leverage to 3.0x net debt/EBITDA by fiscal 2027.
For WELL, Keywood highlighted the sharp expansion in its Canadian clinic M&A pipeline, with assets under letters of intent rising from $48-million to $235-million in targeted revenue quarter-over-quarter. He said this growth suggests balance sheet flexibility, potentially supported by proceeds from a planned U.S. divestiture, and reinforces WELL’s positioning as an active consolidator as healthcare assets come to market.
WELL operates roughly 200 primary-care and related clinics, holds close to 20% EMR market share, and has cybersecurity and U.S. telehealth exposure. Keywood views the company as a consolidator within health-tech, similar in model to Canadian software acquirers such as Enghouse, Descartes and Constellation Software.
Disclosure: Nick Waddell owns shares of WELL Health and the company is an annual sponsor
-30
Loading more…
link